Download Viventia Reports on Progress of Anti

Viventia Reports on Progress of Anti-Cancer Pipeline at PEGS Korea 2015
- Viventia’s Targeted Protein Therapeutics (TPTs) have been designed to overcome the efficacy and
safety challenges of existing antibody-drug conjugates –
WINNIPEG, Manitoba, and Philadelphia, PA, September 4, 2015 -- Viventia Bio Inc., a late clinical-stage company
advancing a broad pipeline of novel anti-cancer agents, announced that Gregory P. Adams, Ph.D., Chief
Development Officer, delivered the keynote presentation (“Targeted Protein Therapeutics (TPTs) for the
Treatment of Cancer”) at the PEGS Korea 2015 Protein and Antibody Engineering Summit, held this week in Seoul,
Republic of Korea. Dr. Adams reviewed the Company’s substantial progress in advancing its proprietary TPT
programs into late-stage clinical testing, as well as earlier-stage programs.
Viventia has initiated its Phase III clinical trial for Vicinium™, which is being developed for subjects with high-grade
non-muscle invasive bladder cancer (NMIBC), and is preparing its Phase III study for Proxinium for the treatment
of late-stage squamous cell carcinoma of the head & neck (SCCHN). These products consist of a single chain
EpCAM-targeting Fab antibody fragment genetically fused to a truncated Pseudomonas exotoxin, or exotoxin A
(ETA), a cytotoxic payload. These products target and bind to cancer cells expressing EpCAM, a protein exclusively
associated with epithelium and overexpressed on many epithelial cancers. Once bound, Vicinium and Proxinium
are internalized and migrate within the cancer cell, where the cytotoxic payload dissociates from the single chain
fragment and is then able to exert its cell-killing activity.
By incorporating antibody fragments, Viventia’s TPTs are designed for a high degree of target specificity in
contrast to existing cancer treatments, such as chemotherapy, which broadly target cells (both cancer and
normal) that have increased mitotic rates, or kinase inhibitors, which can have impacts on off-target kinases.
Viventia’s TPTs also have been designed to overcome the primary challenges experienced by existing antibody
drug conjugates (ADCs), which are frequently associated with poor serum stability, susceptibility to multi-drug
resistance, and decreased efficacy against slowly proliferating cancer cell populations. In contrast, Viventia’s TPTs
have demonstrated tumor targeting and cancer cell-killing properties, as well as linker stability and efficient
manufacturing.
Additional key programs in Viventia’s development pipeline include earlier-stage programs advancing deimmunized, systemic anti-cancer TPT product candidates. VB6-845d is a recombinant protein comprising
antibody fragment genetically fused to deBouganin, a de-immunized form of the plant toxin Bouganin.
deBouganin is a de-immunized cytotoxic payload specifically designed for use in systemic product candidates.
Dr. Adams stated, “We’re pleased to have reported the broad scope of our TPT programs at this year’s PEGS
Korea meeting, considered one of the industry’s leading events focused on protein and antibody engineering. We
believe this was a unique venue to highlight our TPT platform and the expected progress of our programs through
the first part of next year.” Dr. Adams continued, “Based on the current progress and results, we believe our
product candidates hold great potential in addressing significant unmet needs for patients with cancer.”
“I am very proud of our team’s accomplishments and of the accelerated momentum at the Company,” stated
Stephen Hurly, Chief Executive Officer of Viventia. “We are excited by the prospect of our upcoming clinical trials,
which will provide further validation for our TPTs in treating a range of cancer indications.”
About Viventia Bio
Viventia Bio is a late clinical-stage company advancing a broad pipeline of novel anti-cancer agents based on the
Company's Targeted Protein Therapeutics (TPTs) platform. Our TPTs genetically combine antibody-based
fragments with protein toxin payloads to create a single protein molecule through the Company’s proprietary
one-step manufacturing process. The Company believes its TPTs can potentially offer significant advantages in
treating cancer versus earlier targeted therapies, including in tumor targeting and cancer cell-killing properties
through the utilization of protein payloads versus small molecules and the ability to trigger an anti-tumor immune
response, as well as enhanced linker stability and more efficient manufacturing.
Contact:
Justin Jackson, Burns McClellan, on behalf of Viventia Bio
212-213-0006, ext.327
[email protected]